55 summarised stories about Drug Discovery, each linking back to the original source. Browse all topics →
Sifted 1 week ago 28
Rivercell, a Paris-based biotech, raised a $25m seed round to build an AI model aimed at understanding and predicting human cell behavior for drug discovery. The funding amount is $25m. The company will use the money to develop and refine its human-cell “world model” to support faster drug discovery.
The Verge 1 week ago 1 ● 3 sources
Biohub, founded by Mark Zuckerberg and Priscilla Chan, received joint investment from Google DeepMind, Meta, and Isomorphic Labs. The partners put $300 million into the effort within a broader $1.8 billion initiative. The funding is meant to accelerate AI dataset creation for simulations and digital biological question-answering, supporting Biohub’s “virtual cell” research.
The daily briefing
TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.
TLDRocket
15 October 2026
Anthropic’s IPO momentum dominated today’s AI news, and the details read like a pitch built for CFOs, not just researchers. The company told investors its third-quarter revenue hit $16.8 billion, up about 46% quarter over quarter and nearly 50% in the story’s framing, putting it on a clear path toward public-market scrutiny. Crucially for the valuation talk, distillation—how labs compress and reuse model knowledge—contributed only 5% to 7% of revenue before being “cut back materially” in Q3, shifting the mix away from spending and dependencies that other labs leaned on. An early backer’s market-odds math expects shares priced around $1.8 trillion with a trading value of $2.3 to $2.4 trillion, even comparing that jump to SpaceX’s roughly $2.1 trillion opening-day market cap.
Read the full briefing →